Fig. 2. Proteasomal degradation pathway. HEK-293 cell lines stably expressing (A) A1038V, or (B) G1961E were treated for 16 h with increasing doses of proteasome inhibitor MG-132. Data are normalized to the 0 µM control. *P<0.05. n=4. Ezrin was used as the loading control. Mutations A1038V and G1961E are degraded to some extent in the proteasome.